Company HistoryTCRCure Biological Technology Co Ltd.

2016.08

TCRCure founded

TCRCure Chongqing R&D center established
Obtain angel investment from professional investment institutions.

2016.11

2017.05

TCRCure US center established.

Planned for 20+ cell therapy related IP assets
Completed preclinical studies for 5 pipeline products

2018.01

2018.04

POC clinical trial started: TCR-T therapy for cervical and head/neck cancer

Obtain series A funding from professional pharmaceutical factories and investment institutions
TCRCure US and China GMP Center started construction.

2019.01

POC clinical trial started in Xinqiao Hospital: TCR-T with secreted PD1 products for cervical and nasopharynx cancer therapy。

POC clinical trial started in Sun Yat-sen University Cancer Center: TCR-T product for nasopharynx cancer therapy.

2019.08

2019.12

TCRCure US and China GMP Center completed.
Two clinical trials for cervical and nasopharyngeal cancer were conducted in China

2016.08

TCRCure founded
2016.11

TCRCure Chongqing R&D center established
Obtain angel investment from professional investment institutions.
2017.05

TCRCure US center established.
2018.01

Planned for 20+ cell therapy related IP assets
Completed preclinical studies for 5 pipeline products
2018.04

POC clinical trial started: TCR-T therapy for cervical and head/neck cancer
2019.01

Obtain series A funding from professional pharmaceutical factories and investment institutions
TCRCure US and China GMP Center started construction.
2019.01

POC clinical trial started in Xinqiao Hospital: TCR-T with secreted PD1 products for cervical and nasopharynx cancer therapy。
2019.08

POC clinical trial started in Sun Yat-sen University Cancer Center: TCR-T product for nasopharynx cancer therapy.
2019.12

TCRCure US and China GMP Center completed.
Two clinical trials for cervical and nasopharyngeal cancer were conducted in China

Introduction to TCRCure